CSPC PHARMA (01093): SYH2085 tablets have received clinical trial approval in China.

CSPC PHARMA (01093) announced that the SYH2085 tablet developed by the group has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. This product is a chemically innovative drug independently developed by the group, which is a new oral small molecule candidate drug that can inhibit the RNA polymerase acidic protein (PA) endonuclease activity of the influenza virus. The approved clinical indication for this product is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and above. Preclinical studies have shown that this product has a clear, broad-spectrum, and excellent inhibitory effect on both influenza A and B viruses, effectively reducing the viral load and flu-like symptoms in flu animal models, and has good pharmacokinetic characteristics and safety. This product is expected to be an effective drug for treating influenza, with high clinical development value, and will further enrich the group's product pipeline in the field of anti-infective therapy.